Crosstalk between AML and stromal cells triggers acetate secretion through the metabolic rewiring of stromal cells
Abstract
Acute myeloid leukaemia (AML) cells interact and modulate components of their surrounding microenvironment into their own benefit. Stromal cells have been shown to support AML survival and progression through various mechanisms. Nonetheless, whether AML cells could establish beneficial metabolic interactions with stromal cells is underexplored. By using a combination of human AML cell lines and AML patient samples together with mouse stromal cells and a MLL-AF9 mouse model, here we identify a novel metabolic crosstalk between AML and stromal cells where AML cells prompt stromal cells to secrete acetate for their own consumption to feed the tricarboxylic acid cycle (TCA) and lipid biosynthesis. By performing transcriptome analysis and tracer-based metabolic NMR analysis, we observe that stromal cells present a higher rate of glycolysis when co-cultured with AML cells. We also find that acetate in stromal cells is derived from pyruvate via chemical conversion under the influence of reactive oxygen species (ROS) following ROS transfer from AML to stromal cells via gap junctions. Overall, we present a unique metabolic communication between AML and stromal cells and propose two different molecular targets, ACSS2 and gap junctions, that could potentially be exploited for adjuvant therapy.
Data availability
RNA-seq data has been deposited in GEO under accession number GSE163478.All data generated or analysed during this study are included in the manuscript and supporting file; Source Data files have been provided for all figures.Information about AML patient samples obtained from Martini Hospital (UMCG) (Netherlands) and University Hospital Birmingham NHS Foundation Trust, University of Birmingham (UK) have been provided in supplementary Table 1.Source of mice used can be found in Material and methods.
Article and author information
Author details
Funding
Horizon 2020 Framework Programme (H2020-MSCA-ITN-2015-675790)
- Nuria Vilaplana-Lopera
- Grigorios Papatzikas
- Alan Cunningham
- Ayşegül Erdem
European Commission (HaemMetabolome [EC-675790])
- Jean-Baptiste Cazier
European Commission (HaemMetabolome [EC-675790])
- Jan Jacob Schuringa
European Commission (HaemMetabolome [EC-675790])
- Ulrich Günther
European Commission (HaemMetabolome [EC-675790])
- Paloma Garcia
European Commission (HaemMetabolome [EC-675790)
- Frank Schnütgen
- Jean-Baptiste Cazier
- Jan Jacob Schuringa
- Ulrich Günther
- Paloma Garcia
Deutsche Forschungsgemeinschaft (SFB815,TP A10)
- Frank Schnütgen
Wellcome Trust (208400/Z/17/Z)
- Ulrich Günther
Helse Nord RHF (2014/5668)
- Lorena Arranz
University of Birmingham (67262-DIF Post-Covid Support Fund)
- Paloma Garcia
Horizon 2020 Framework Programme (H2020-MSCA-ITN-2015-675790)
- Grigorios Papatzikas
Horizon 2020 Framework Programme (H2020-MSCA-ITN-2015-675790)
- Alan Cunningham
Horizon 2020 Framework Programme (H2020-MSCA-ITN-2015-675790)
- Ayşegül Erdem
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: Animal experiments were conducted with the ethical approval of the Norwegian Food and Safety Authority under project number 19472, with a particular focus on reduction and refinement. Animals were housed under specific opportunistic and pathogen free environment at the Animal Facility of the University of Oslo, Norway. The animals were euthanized by CO2 and absence of reflexes was confirmed before necropsy.
Human subjects: AML and PBMC primary specimens' procedures were obtained in accordance with the Declaration of Helsinki at the University Medical Center Groningen, approved by the UMCG Medical Ethical Committee or at the University Hospital Birmingham NHS Foundation Trust, approved by the West Midlands - Solihull Research Ethics Committee (10/H1206//58).
Copyright
© 2022, Vilaplana-Lopera et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,510
- views
-
- 516
- downloads
-
- 11
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Biochemistry and Chemical Biology
- Genetics and Genomics
RNA binding proteins (RBPs) containing intrinsically disordered regions (IDRs) are present in diverse molecular complexes where they function as dynamic regulators. Their characteristics promote liquid-liquid phase separation (LLPS) and the formation of membraneless organelles such as stress granules and nucleoli. IDR-RBPs are particularly relevant in the nervous system and their dysfunction is associated with neurodegenerative diseases and brain tumor development. Serpine1 mRNA-binding protein 1 (SERBP1) is a unique member of this group, being mostly disordered and lacking canonical RNA-binding domains. We defined SERBP1’s interactome, uncovered novel roles in splicing, cell division and ribosomal biogenesis, and showed its participation in pathological stress granules and Tau aggregates in Alzheimer’s brains. SERBP1 preferentially interacts with other G-quadruplex (G4) binders, implicated in different stages of gene expression, suggesting that G4 binding is a critical component of SERBP1 function in different settings. Similarly, we identified important associations between SERBP1 and PARP1/polyADP-ribosylation (PARylation). SERBP1 interacts with PARP1 and its associated factors and influences PARylation. Moreover, protein complexes in which SERBP1 participates contain mostly PARylated proteins and PAR binders. Based on these results, we propose a feedback regulatory model in which SERBP1 influences PARP1 function and PARylation, while PARylation modulates SERBP1 functions and participation in regulatory complexes.
-
- Biochemistry and Chemical Biology
Missense mutations in the amyloid precursor protein (APP) and presenilin-1 (PSEN1) cause early-onset familial Alzheimer’s disease (FAD) and alter proteolytic production of secreted 38-to-43-residue amyloid β-peptides (Aβ) by the PSEN1-containing γ-secretase complex, ostensibly supporting the amyloid hypothesis of pathogenesis. However, proteolysis of APP substrate by γ-secretase is processive, involving initial endoproteolysis to produce long Aβ peptides of 48 or 49 residues followed by carboxypeptidase trimming in mostly tripeptide increments. We recently reported evidence that FAD mutations in APP and PSEN1 cause deficiencies in early steps in processive proteolysis of APP substrate C99 and that this results from stalled γ-secretase enzyme-substrate and/or enzyme-intermediate complexes. These stalled complexes triggered synaptic degeneration in a Caenorhabditis elegans model of FAD independently of Aβ production. Here, we conducted full quantitative analysis of all proteolytic events on APP substrate by γ-secretase with six additional PSEN1 FAD mutations and found that all six are deficient in multiple processing steps. However, only one of these (F386S) was deficient in certain trimming steps but not in endoproteolysis. Fluorescence lifetime imaging microscopy in intact cells revealed that all six PSEN1 FAD mutations lead to stalled γ-secretase enzyme-substrate/intermediate complexes. The F386S mutation, however, does so only in Aβ-rich regions of the cells, not in C99-rich regions, consistent with the deficiencies of this mutant enzyme only in trimming of Aβ intermediates. These findings provide further evidence that FAD mutations lead to stalled and stabilized γ-secretase enzyme-substrate and/or enzyme-intermediate complexes and are consistent with the stalled process rather than the products of γ-secretase proteolysis as the pathogenic trigger.